Literature DB >> 1528902

Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry.

A B Sabin.   

Abstract

The worldwide effort to produce a vaccine against AIDS continues to disregard the fact that even human immunodeficiency virus (HIV)-specific neutralizing antibodies and cell-mediated immunity are ineffective against virus within cells without viral antigens on the cell membrane--and that much of HIV infection is transmitted in this manner. According to a recent report, a simian immunodeficiency virus vaccine that protected monkeys against an intravenous challenge with cell-free virus was, as predicted, ineffective against an intravenous challenge with the same amount of virus in infected cells. Moreover, antibody and HIV have been found to coexist in cell-free plasma from asymptomatic and symptomatic patients. Excluding direct introduction of HIV into the blood-stream, the most common and efficient form of transmission of HIV infection is by receptive anal intercourse, and semen contains large numbers of infected cells per milliliter. Recent reports showing that colorectal cells can be persistently infected by HIV and that HIV RNA and cDNA are present in the cells of the colon of dead AIDS patients indicate that either cell-free or intracellular HIV has the capacity to multiply at the portal of entry in the colorectal area without interference from neutralizing antibodies. The available data provide no basis for testing any HIV vaccine in human beings either before or after infection. The main challenge is to find a way to kill cells with chromosomally integrated HIV cDNA without harming normal cells, perhaps by identifying repressor proteins that might be produced by the cells with integrated HIV cDNA and thus could become specific targets for cell-killing drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1528902      PMCID: PMC50019          DOI: 10.1073/pnas.89.18.8852

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Effectiveness of AIDS vaccines.

Authors:  A B Sabin
Journal:  Science       Date:  1991-03-08       Impact factor: 47.728

2.  Anti-cell antibody in macaques.

Authors:  E J Stott
Journal:  Nature       Date:  1991-10-03       Impact factor: 49.962

3.  Prevention of HIV infection by passive immunization with HIV immunoglobulin.

Authors:  A M Prince; H Reesink; D Pascual; B Horowitz; I Hewlett; K K Murthy; K E Cobb; J W Eichberg
Journal:  AIDS Res Hum Retroviruses       Date:  1991-12       Impact factor: 2.205

4.  AIDS vaccine developments.

Authors:  M P Cranage; L A Ashworth; P J Greenaway; M Murphey-Corb; R C Desrosiers
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

5.  AIDS vaccine developments.

Authors:  R Le Grand; B Vaslin; G Vogt; P Roques; M Humbert; D Dormont
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

6.  AIDS vaccine developments.

Authors:  A Osterhaus; P de Vries; J Heeney
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

7.  Mucosal transmission of HIV.

Authors:  T Lehner; L Hussain; J Wilson; M Chapman
Journal:  Nature       Date:  1991-10-24       Impact factor: 49.962

8.  Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics.

Authors:  A R Lifson; S P Buchbinder; H W Sheppard; A C Mawle; J C Wilber; M Stanley; C E Hart; N A Hessol; S D Holmberg
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

9.  Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells.

Authors:  P N Fultz; P Nara; F Barre-Sinoussi; A Chaput; M L Greenberg; E Muchmore; M P Kieny; M Girard
Journal:  Science       Date:  1992-06-19       Impact factor: 47.728

10.  Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences.

Authors:  A Shafferman; P B Jahrling; R E Benveniste; M G Lewis; T J Phipps; F Eden-McCutchan; J Sadoff; G A Eddy; D S Burke
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

View more
  14 in total

1.  Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; I Lonetti; L Zaccaro; C Pollera; S Specter; M Bendinelli
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity--hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-01       Impact factor: 2.332

3.  The Trojan exosome hypothesis.

Authors:  Stephen J Gould; Amy M Booth; James E K Hildreth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-28       Impact factor: 11.205

4.  Specific-antibody-secreting cells in the rectums and genital tracts of nonhuman primates following vaccination.

Authors:  K Eriksson; M Quiding-Järbrink; J Osek; A Möller; S Björk; J Holmgren; C Czerkinsky
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

5.  Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice.

Authors:  M Lagranderie; A M Balazuc; B Gicquel; M Gheorghiu
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination.

Authors:  S J Kent; S L Hu; L Corey; W R Morton; P D Greenberg
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120.

Authors:  Y Furuta; K Eriksson; B Svennerholm; P Fredman; P Horal; S Jeansson; A Vahlne; J Holmgren; C Czerkinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 8.  The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers--a review and hypothesis.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

Review 9.  HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.

Authors:  Y Becker
Journal:  Virus Genes       Date:  1994-07       Impact factor: 2.332

10.  A proposal for a new approach to a preventive vaccine against human immunodeficiency virus type 1.

Authors:  H M Temin
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.